-
EP4259149
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4259149
| EP4259149 - EGANELISIB FOR USE IN THE TREATMENT OF PD-L1 NEGATIVE CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 24.01.2025 Database last updated on 09.04.2026 | |
| Former | Request for examination was made Status updated on 15.09.2023 | ||
| Former | The international publication has been made Status updated on 17.06.2022 | ||
| Former | unknown Status updated on 10.01.2022 | Most recent event Tooltip | 26.02.2026 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Twelve Therapeutics, Inc. 345 Park Avenue South, 12th Floor New York, NY 10010 / US | [2025/48] |
| Former [2023/42] | For all designated states Infinity Pharmaceuticals, Inc. 1100 Massachusetts Avenue, 4th Floor Cambridge, MA 02138 / US | Inventor(s) | 01 /
O'CONNELL, Brenda Carol Brighton, MA 02135 / US | [2023/42] | Representative(s) | Jones Day Gewürzmühlstr. 11 80538 München / DE | [N/P] |
| Former [2023/42] | Jones Day Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11 80538 München / DE | Application number, filing date | 21835092.4 | 07.12.2021 | [2023/42] | WO2021US62127 | Priority number, date | US202063122892P | 08.12.2020 Original published format: US 202063122892 P | US202163146470P | 05.02.2021 Original published format: US 202163146470 P | US202163168123P | 30.03.2021 Original published format: US 202163168123 P | US202163203515P | 26.07.2021 Original published format: US 202163203515 P | [2023/42] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022125497 | Date: | 16.06.2022 | Language: | EN | [2022/24] | Type: | A1 Application with search report | No.: | EP4259149 | Date: | 18.10.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.06.2022 takes the place of the publication of the European patent application. | [2023/42] | Search report(s) | International search report - published on: | EP | 16.06.2022 | Classification | IPC: | A61K31/519, A61K39/395, A61K31/337, A61P35/00 | [2023/42] | CPC: |
A61K31/519 (EP,US);
A61K31/337 (EP,US);
A61K39/3955 (EP,US);
A61P35/00 (EP,US);
A61P35/04 (US);
C07K16/2818 (US);
C07K16/2827 (US);
A61K2039/505 (US);
C07K2317/21 (US);
C07K2317/24 (US)
(-)
| C-Set: |
A61K31/519, A61K39/395, A61K2300/00 (EP,US);
A61K39/3955, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/42] | Title | German: | EGANELISIB ZUR VERWENDUNG BEI DER BEHANDLUNG VON PD-L1-NEGATIVEM KREBS | [2023/42] | English: | EGANELISIB FOR USE IN THE TREATMENT OF PD-L1 NEGATIVE CANCER | [2023/42] | French: | ÉGANÉLISIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT D'UN CANCER PD-L1 NÉGATIF | [2023/42] | Entry into regional phase | 06.06.2023 | National basic fee paid | 06.06.2023 | Designation fee(s) paid | 06.06.2023 | Examination fee paid | Examination procedure | 06.06.2023 | Examination requested [2023/42] | 06.06.2023 | Date on which the examining division has become responsible | 20.02.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 20.02.2024 | Despatch of communication of loss of particular rights: Claims {1} | 19.04.2024 | Amendment by applicant (claims and/or description) | 28.01.2025 | Despatch of a communication from the examining division (Time limit: M06) | 25.07.2025 | Reply to a communication from the examining division | 25.02.2026 | Despatch of a communication from the examining division (Time limit: M04) | Request for further processing for: | 19.04.2024 | Request for further processing filed | 19.04.2024 | Full payment received (date of receipt of payment) Request granted | 25.04.2024 | Decision despatched | 19.04.2024 | Request for further processing filed | 19.04.2024 | Full payment received (date of receipt of payment) Request granted | 25.04.2024 | Decision despatched | Fees paid | Renewal fee | 27.12.2023 | Renewal fee patent year 03 | 27.12.2024 | Renewal fee patent year 04 | 29.12.2025 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YP] WO2021004421 (ZHEJIANG HISUN PHARM CO LTD et al.) | [XPY] PORTMAN N ET AL: "Mario-3 phase II study safety run-inevaluating a novel triplet combination of eganelisib(formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locallyadvanced or metastatic triple-negative breast cancer(TNBC)", CANCER RESEARCH 20210201 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. NLD, vol. 81, no. 4 SUPPL, 8 December 2020 (2020-12-08), & 2020 San Antonio Breast Cancer Symposium, 08 - 11 Dec 2020, XP002805808, ISSN: 1538-7445 | [XPY] TOMCZAK P ET AL: "Preliminary analysis of a phase II, multicenter, randomized, activecontrol study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma", JOURNAL OF CLINICAL ONCOLOGY 20210201 AMERICAN SOCIETY OF CLINICAL ONCOLOGY NLD, vol. 39, no. 6 SUPPL, 1 February 2021 (2021-02-01), & 2021 Genitourinary Cancers Symposium 11 - 13 Jan 2021, XP002805809, ISSN: 1527-7755 | [Y] SULLIVAN R J ET AL: "Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors", JOURNAL OF CLINICAL ONCOLOGY 20180501 AMERICAN SOCIETY OF CLINICAL ONCOLOGY NLD, vol. 36, no. 15, Supplement 1, 1 May 2018 (2018-05-01), & 2018 Annual Meeting of the American Society of Clinical Oncology, ASCO 01 - 05 Jun 2018, XP002805821, ISSN: 1527-7755 | [Y] TOLCHER A: "IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-[gamma] inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors", CANCER RESEARCH 20170701 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. NLD, vol. 77, no. 13, Supplement 1, 1 July 2017 (2017-07-01), & American Association for Cancer Research Annual Meeting, Washington DC 01 - 05 Apr 2017, XP002805822, ISSN: 1538-7445 | Examination | US2018055852 | DE HENAU OLIVIER ET AL: "Overcoming resistance to checkpoint blockade therapy by targeting PI3K[gamma] in myeloid cells", NATURE, vol. 539, no. 7629, 1 November 2016 (2016-11-01), pages 443 - 447, XP055773634, Retrieved from the Internet DOI: http://dx.doi.org/10.1038/nature20554 | by applicant | US2013295102 | WO2015051244 | WO2015143012 | WO2017048702 | WO2011041399 | US2010029693 | US2010305096 | US2010305084 | US8008449 | WO2006121168 | WO2009114335 | US8354509 | WO2009101611 | US8609089 | US2010028330 | US2012114649 | WO2007005874 | WO2010077634 | US7943743 | US2012039906 | WO2010027827 | WO2011066342 | US2011150892 | WO2010019570 | WO2014008218 | US6111090 | EP0090505 | US8586023 | WO2010003118 | WO2011090754 | US7025962 | EP1947183 | US7812135 | US8388967 | US8591886 | EP1866339 | WO2011028683 | WO2013039954 | WO2005007190 | WO2007133822 | WO2005055808 | WO9940196 | WO0103720 | WO9920758 | WO2006083289 | WO2005115451 | US7618632 | WO2011051726 | GAESTEL ET AL., CURRENT MEDICINAL CHEMISTRY, vol. 14, 2007, pages 2214 - 2234 | CHOU ET AL., ADV ENZYME REGUL, vol. 22, 1984, pages 27 - 55 | VANHAESEBROECK, B. ET AL., ANNU REV BIOCHEM., vol. 70, 2001, pages 535 - 602 | BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 | "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE | WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 | "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL | "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 | FUNG-LEUNG WP., CELL SIGNAL., vol. 23, no. 4, 2011, pages 603 - 8 | VANHAESEBROECK, B. ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, DOI 10.1007/82 2010 65, 2010 | HARRIS, SJ ET AL., CURR OPIN INVESTIG DRUGS, vol. 10, no. 11, 2009, pages 1151 - 62 | ROMMEL C. ET AL., NAT REV IMMUNOL, vol. 7, no. 3, 2007, pages 191 - 201 | DURAND CA ET AL., J IMMUNOL., vol. 183, no. 9, 2009, pages 5673 - 84 | DIL NMARSHALL AJ., MOL IMMUNOL., vol. 46, no. 10, 2009, pages 1970 - 8 | AL-ALWAN MM ET AL., J IMMUNOL., vol. 178, no. 4, 2007, pages 2328 - 35 | ZHANG TT ET AL., J ALLERGY CLIN IMMUNOL., vol. 122, no. 4, 2008, pages 811 - 819 | SRINIVASAN L ET AL., CELL, vol. 139, no. 3, 2009, pages 573 - 86 | HIRSCH ET AL.: "Central Role for G Protein-Coupled Phosphoinositide 3-Kinase y in Inflammation", SCIENCE, vol. 287, 2000, pages 1049 - 1053 | SASAKI ET AL.: "Function of PI3Ky in Thymocyte Development, T Cell Activation, and Neutrophil Migration", SCIENCE, vol. 287, 2000, pages 1040 - 1046, XP002214938, DOI: 10.1126/science.287.5455.1040 DOI: http://dx.doi.org/10.1126/science.287.5455.1040 | LI ET AL.: "Roles of PLC-p2 and -(33 and PI3Ky in Chemoattractant-Mediated Signal Transduction", SCIENCE, vol. 287, 2000, pages 1046 - 1049 | RANDIS ET AL., EUR. J. IMMUNOL., vol. 38, no. 5, 2008, pages 1215 - 24 | TAKEDA ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 123, 2009, pages 805 - 12 | SASAKI ET AL., SCIENCE, vol. 287, 2000, pages 1040 - 46 | ROLLER ET AL.: "Blockade of Phosphatidylinositol 3-Kinase (PI3K) or PI3Ky Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis", J. IMMUNOL., vol. 189, 2012, pages 4612 - 4620, XP055065662, DOI: 10.4049/jimmunol.1103173 DOI: http://dx.doi.org/10.4049/jimmunol.1103173 | SCHMID ET AL., CANCER CELL, vol. 19, 2011, pages 715 - 727 | HARDAMON: "Proceedings: AACR 103rd Annual Meeting 2012", CANCER RESEARCH, vol. 72, 15 April 2012 (2012-04-15) | SUBRAMANIAM ET AL., CANCER CELL, vol. 21, 2012, pages 459 - 472 | BURGER: "Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia", CURR. MEMATOL. MALIG. REP., vol. 7, 2012, pages 26 - 33, XP035015776, DOI: 10.1007/s11899-011-0104-z DOI: http://dx.doi.org/10.1007/s11899-011-0104-z | RUCKLE ET AL., NATURE REV., DRUG DISCOVERY, vol. 5, 2006, pages 903 - 18 | SCHMID ET AL.: "Myeloid cells in tumor inflammation", VASCULAR CELL, 2012 | EDLING ET AL., HUMAN CANCER BIOLOGY, vol. 16, no. 2, 2010, pages 4928 - 37 | VOGT, PK ET AL., CURR TOP MICROBIOL IMMUNOL., vol. 347, 2010, pages 169 - 104 | FRESNO VARA, JA ET AL., CANCER TREAT REV, vol. 30, no. 2, 2004, pages 193 - 204 | ZHAO, LVOGT, PK, ONCOGENE, vol. 27, no. 41, 2008, pages 5486 - 96 | COURTNEY, KD ET AL., J CLIN ONCOL., vol. 28, no. 6, 2010, pages 1075 - 1083 | MARKMAN, B ET AL., ANN ONCOL., vol. 21, no. 4, 2010, pages 683 - 91 | KONG, DYAMORI, T, CURR MED CHEM., vol. 16, no. 22, 2009, pages 2839 - 54 | WAGNER, AJ ET AL., J CLIN ONCOL., vol. 27, 2009, pages 146s | VOGT, PK ET AL., VIROLOGY, vol. 344, no. 1, 2006, pages 131 - 8 | WARD, S ET AL., CHEM BIOL., vol. 10, no. 3, 2003, pages 207 - 13 | SALMENA, L ET AL., CELL, vol. 133, 2008, pages 403 - 414 | CHAPUIS, N ET AL., CLIN CANCER RES., vol. 16, no. 22, 2010, pages 5424 - 35 | HERRERA, VA ET AL., ANTICANCER RES., vol. 31, no. 3, 2011, pages 849 - 54 | HALUSKA, F ET AL., SEMIN ONCOL., vol. 34, no. 6, 2007, pages 546 - 54 | SARKER, D ET AL., CLIN CANCER RES., vol. 15, no. 15, 2009, pages 4799 - 805 | CHEN J.S. ET AL., MOL CANCER THER., vol. 7, no. 4, 2008, pages 841 - 850 | BANSAL, N ET AL., CANCER CONTROL., vol. 16, no. 1, 2009, pages 8 - 13 | FURUKAWA, T, J GASTROENTEROL., vol. 43, no. 12, 2008, pages 905 - 11 | PORTA, CFIGLIN, RA, J UROL., vol. 182, no. 6, 2009, pages 2569 - 77 | SAIF, MWCHU, E, CANCER J., vol. 16, no. 3, 2010, pages 196 - 201 | TORBETT, NE ET AL., BIOCHEM J., vol. 415, 2008, pages 97 - 100 | BRZEZIANSKA, EPASTUSZAK-LEWANDOSKA, D, FRONT BIOSCI., vol. 16, 2011, pages 422 - 39 | MAZZOLETTI, MBROGGINI, M, CURR MED CHEM., vol. 17, no. 36, 2010, pages 4433 - 47 | HERMAN SE ET AL., BLOOD, vol. 116, no. 12, 2010, pages 2078 - 88 | BILLOTTET C ET AL., ONCOGENE, vol. 25, no. 50, 2006, pages 6648 - 59 | BILLOTTET C ET AL., CANCER RES., vol. 69, no. 3, 2009, pages 1027 - 36 | HOELLENRIEGEL, J ET AL., 52ND ANNUAL ASH MEETING AND EXPOSITION, 4 December 2010 (2010-12-04) | HERMAN SE ET AL., BLOOD, vol. 117, no. 16, 2011, pages 4323 - 7 | PROCEEDINGS OF THE 105TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 5 April 2014 (2014-04-05) | CANCER RES, vol. 74, 2014 | CLAIRE E. LEWIS: "Imaging immune cell infiltrating tumors in zebrafish", AACR ANNUAL MEETING, 5 April 2014 (2014-04-05) | LEWISPOLLARD, CANCER RES., vol. 66, no. 2, 15 January 2006 (2006-01-15) | COUSSENS LM. ET AL., CANCER DISCOV., June 2011 (2011-06-01), pages 54 - 67 | HAMID, O. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 2, 2013, pages 134 - 44 | CANCER RES, vol. 73, no. 12, 15 June 2013 (2013-06-15) | CURRAN M A ET AL., PNAS, vol. 107, 2010, pages 4275 - 4280 | TOPALIAN ET AL., N ENGL J MED, vol. 366, 2012, pages 2443 - 2454 | WOLCHOK ET AL., NEJM, 2013, pages 369 | CAS , no. 477202-00-9 | CANCER CELL, vol. 25, 16 June 2014 (2014-06-16), pages 1 - 14 | SCHMID ET AL.: "Proceedings: AACR 103rd Annual Meeting", CANCER RESEARCH, vol. 72, 15 April 2012 (2012-04-15) | CHEUNG ET AL., APPL. IMMUNOHISTOCHEM. MOL. MORPHOL., vol. 27, no. 10, 2019, pages 699 - 714 | DAVIS ET AL., JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, 2019 | KIM ET AL., J THORAC. ONCOL., vol. 13, no. 5, 2018, pages 636 - 648 | POWLES ET AL., LANCET, 2020 | PATEL ET AL., LANCET, 2018 | BELLMUNT ET AL., NEJM, 2017 | ROSENBERG ET AL., LANCET, 2016 | ZAJAC, PLOS ONE, 2020 | GALSKY ET AL., CLIN CAN RES, 2020 | VUKY ET AL., JCO, 2020 | BALAR ET AL., LANCET, 2017 |